Featured Story

  • Amarantus, Anavex team up for Alzheimer's biomarker Dx

    Amarantus BioSciences Holdings struck a deal with Anavex Life Sciences to provide biomarker test services for the company's Alzheimer's drug candidates, a major win for Amarantus as it looks to expand the reach of its blood-based diagnostic test.

RainDance waltzes toward $60M IPO

RainDance Technologies is moving one step closer to completing its long-awaited IPO, filing plans for a $60 million offering to cash in on a growing market for its next-generation sequencing tools.

Skin test could vastly simplify diagnosis of Alzheimer's and Parkinson's

Researchers have discovered that a skin sample taken from behind the ear of patients with either Alzheimer's or Parkinson's disease had levels of the protein tau 7 times higher than those without the condition. Those with Parkinson's showed levels of alpha-synuclein protein that were 8 times higher than those in the control group.

Exact Sciences beefs up sales and reimbursement efforts for colon cancer Dx

Exact Sciences is charting big plans for 2015, increasing its sales efforts and pushing for expanded coverage of its stool-based DNA colon cancer test to grab a bigger market share.

Vigilant Biosciences reels in $5.5M for oral cancer test

Vigilant Biosciences roped in $5.5 million in a Series B round to support development of its diagnostic system for the early detection of oral cancer, giving the company a boost as it eyes European and stateside approval for its product.

Roche, BioMed X to jointly run diagnostics incubator in Germany

Roche and BioMed X are teaming up to create a diagnostics research group focused on biosensors and nanomaterials such as graphene within BioMed X's open innovation lab in Heidelberg, Germany. 


From Our Sister Sites


Smith & Nephew was down 8% on the March 3 news that Stryker now has a massive $2.6 billion authorization available for share repurchases. That's a significant shift in strategy for Stryker, which has been highly acquisitive in the last few years and has long been rumored as a potential buyer for Smith & Nephew.


Amgen just announced the debut of the Neulasta Delivery Kit to automatically deliver the medication for infection prevention among cancer patients about 27 hours after chemotherapy, thereby ensuring compliance with the dosing instructions.